CR20170352A - Terapias de combinación para el tratamiento de cánceres - Google Patents
Terapias de combinación para el tratamiento de cánceresInfo
- Publication number
- CR20170352A CR20170352A CR20170352A CR20170352A CR20170352A CR 20170352 A CR20170352 A CR 20170352A CR 20170352 A CR20170352 A CR 20170352A CR 20170352 A CR20170352 A CR 20170352A CR 20170352 A CR20170352 A CR 20170352A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer treatment
- combination therapies
- cancer
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- XSMSNFMDVXXHGJ-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XSMSNFMDVXXHGJ-UHFFFAOYSA-N 0.000 abstract 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 abstract 1
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 229950004136 entospletinib Drugs 0.000 abstract 1
- 229950004847 navitoclax Drugs 0.000 abstract 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001183 venetoclax Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en el presente documento métodos que se relacionan con una estrategia terapéutica para el tratamiento del cáncer, incluyendo malignidades hematológicas. En particular, los métodos incluyen la administración de entospletinib y un inhibidor de Bcl-2, tal como venetoclax, navitoclax y ABT-737.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111604P | 2015-02-03 | 2015-02-03 | |
PCT/US2016/015727 WO2016126552A1 (en) | 2015-02-03 | 2016-01-29 | Combination therapies for treating cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20170352A true CR20170352A (es) | 2017-09-29 |
Family
ID=55398445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20170352A CR20170352A (es) | 2015-02-03 | 2016-01-29 | Terapias de combinación para el tratamiento de cánceres |
Country Status (25)
Country | Link |
---|---|
US (2) | US20160220573A1 (es) |
EP (1) | EP3253385A1 (es) |
JP (1) | JP2018503653A (es) |
KR (1) | KR20170104616A (es) |
CN (1) | CN107205992A (es) |
AU (1) | AU2016215643A1 (es) |
BR (1) | BR112017016019A2 (es) |
CA (1) | CA2974828A1 (es) |
CL (1) | CL2017001943A1 (es) |
CO (1) | CO2017007662A2 (es) |
CR (1) | CR20170352A (es) |
CU (1) | CU20170099A7 (es) |
EA (1) | EA201791516A1 (es) |
EC (1) | ECSP17048849A (es) |
GT (1) | GT201700167A (es) |
IL (1) | IL253573A0 (es) |
MA (1) | MA41449A (es) |
MD (1) | MD20170073A2 (es) |
MX (1) | MX2017009724A (es) |
PE (1) | PE20171241A1 (es) |
PH (1) | PH12017550063A1 (es) |
SG (1) | SG11201706107SA (es) |
SV (1) | SV2017005489A (es) |
TW (1) | TW201639573A (es) |
WO (1) | WO2016126552A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104059073B (zh) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | 咪唑并哌嗪syk抑制剂 |
KR101717809B1 (ko) | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | 이미다조피리딘 syk 억제제 |
ES2822285T3 (es) * | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
AU2014296184B2 (en) | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
KR20180002888A (ko) | 2013-12-04 | 2018-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CN108137578B (zh) * | 2016-09-14 | 2021-02-05 | 杭州领业医药科技有限公司 | Abt-199加成盐及其晶型、其制备方法和药物组合物 |
US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
WO2018200841A1 (en) * | 2017-04-28 | 2018-11-01 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
CN111801320A (zh) | 2018-01-10 | 2020-10-20 | 里科瑞尔姆Ip控股有限责任公司 | 苯甲酰胺化合物 |
CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
MA56206A (fr) | 2019-06-12 | 2022-04-20 | Juno Therapeutics Inc | Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie |
WO2021110136A1 (en) * | 2019-12-04 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
EP4316494A1 (en) * | 2021-04-05 | 2024-02-07 | Pinotbio, Inc. | Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
CA2566609C (en) | 2004-05-13 | 2012-06-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
JP5312459B2 (ja) | 2007-08-02 | 2013-10-09 | ジリード バイオロジクス,インク. | Loxおよびloxl2阻害剤ならびにこれらの使用 |
US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
CN104744476B (zh) * | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | 咪唑并吡嗪syk抑制剂 |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
NZ598461A (en) | 2009-09-20 | 2013-12-20 | Abbvie Inc | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
SG183174A1 (en) | 2010-02-04 | 2012-09-27 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
NZ606880A (en) | 2010-08-27 | 2015-01-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
US9550835B2 (en) | 2011-08-23 | 2017-01-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-DDR1 antibody having anti-tumor activity |
GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
JP2015529195A (ja) * | 2012-08-14 | 2015-10-05 | ギリアード カリストガ エルエルシー | 癌を処置するための組合せ治療 |
US9539251B2 (en) * | 2012-09-07 | 2017-01-10 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
WO2014047624A1 (en) | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
PT2941426T (pt) | 2012-12-21 | 2018-07-18 | Gilead Calistoga Llc | Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase |
ES2685568T3 (es) | 2012-12-21 | 2018-10-10 | Gilead Calistoga Llc | Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa |
SI3008053T1 (en) | 2013-06-14 | 2018-06-29 | Gilead Calistoga Llc | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS |
SI3027171T1 (sl) * | 2013-07-30 | 2020-08-31 | Gilead Connecticut, Inc. | Formulacija inhibitorjev SYK |
ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
EP2886146A1 (en) * | 2013-12-20 | 2015-06-24 | Sanofi-Aventis Deutschland GmbH | Needle safety device and drug delivery device |
-
2016
- 2016-01-21 TW TW105101876A patent/TW201639573A/zh unknown
- 2016-01-28 MA MA041449A patent/MA41449A/fr unknown
- 2016-01-29 SG SG11201706107SA patent/SG11201706107SA/en unknown
- 2016-01-29 EA EA201791516A patent/EA201791516A1/ru unknown
- 2016-01-29 AU AU2016215643A patent/AU2016215643A1/en not_active Abandoned
- 2016-01-29 KR KR1020177023454A patent/KR20170104616A/ko not_active Application Discontinuation
- 2016-01-29 CU CUP2017000099A patent/CU20170099A7/es unknown
- 2016-01-29 US US15/010,906 patent/US20160220573A1/en not_active Abandoned
- 2016-01-29 BR BR112017016019A patent/BR112017016019A2/pt not_active Application Discontinuation
- 2016-01-29 US US15/548,401 patent/US20180117052A1/en not_active Abandoned
- 2016-01-29 MX MX2017009724A patent/MX2017009724A/es unknown
- 2016-01-29 CA CA2974828A patent/CA2974828A1/en not_active Abandoned
- 2016-01-29 CN CN201680007860.5A patent/CN107205992A/zh active Pending
- 2016-01-29 PE PE2017001282A patent/PE20171241A1/es not_active Application Discontinuation
- 2016-01-29 MD MDA20170073A patent/MD20170073A2/ro not_active Application Discontinuation
- 2016-01-29 WO PCT/US2016/015727 patent/WO2016126552A1/en active Application Filing
- 2016-01-29 EP EP16705384.2A patent/EP3253385A1/en not_active Withdrawn
- 2016-01-29 CR CR20170352A patent/CR20170352A/es unknown
- 2016-01-29 JP JP2017539623A patent/JP2018503653A/ja active Pending
-
2017
- 2017-07-19 IL IL253573A patent/IL253573A0/en unknown
- 2017-07-27 GT GT201700167A patent/GT201700167A/es unknown
- 2017-07-28 SV SV2017005489A patent/SV2017005489A/es unknown
- 2017-07-28 EC ECIEPI201748849A patent/ECSP17048849A/es unknown
- 2017-07-28 CL CL2017001943A patent/CL2017001943A1/es unknown
- 2017-07-28 CO CONC2017/0007662A patent/CO2017007662A2/es unknown
- 2017-07-31 PH PH12017550063A patent/PH12017550063A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201706107SA (en) | 2017-08-30 |
CO2017007662A2 (es) | 2017-10-20 |
PH12017550063A1 (en) | 2018-02-05 |
MA41449A (fr) | 2017-12-12 |
MX2017009724A (es) | 2017-11-17 |
PE20171241A1 (es) | 2017-08-24 |
US20180117052A1 (en) | 2018-05-03 |
CU20170099A7 (es) | 2018-03-13 |
BR112017016019A2 (pt) | 2018-03-20 |
SV2017005489A (es) | 2017-10-17 |
CA2974828A1 (en) | 2016-08-11 |
EP3253385A1 (en) | 2017-12-13 |
US20160220573A1 (en) | 2016-08-04 |
WO2016126552A1 (en) | 2016-08-11 |
AU2016215643A1 (en) | 2017-08-10 |
CL2017001943A1 (es) | 2018-03-02 |
ECSP17048849A (es) | 2017-10-31 |
JP2018503653A (ja) | 2018-02-08 |
IL253573A0 (en) | 2017-09-28 |
TW201639573A (zh) | 2016-11-16 |
KR20170104616A (ko) | 2017-09-15 |
EA201791516A1 (ru) | 2018-01-31 |
CN107205992A (zh) | 2017-09-26 |
MD20170073A2 (ro) | 2018-02-28 |
GT201700167A (es) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17048849A (es) | Terapias de combinación para el tratamiento de cánceres | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
CR20180228A (es) | Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma | |
UY36075A (es) | Derivados de tubulisina | |
CL2015002807A1 (es) | Terapia de combinación | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. |